Genedata Signs Multi-Year Licensing Agreement with Chugai Pharmaceuticals

Leading Japanese Pharmaceutical Company Uses Genedata Expressionist for Internal R&D

 

Basel, Switzerland, June 29, 2009

Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, and Chugai Pharmaceutical Co., Ltd., a leading Japanese research-based pharmaceutical company, have signed a multi-year contract for the use of the Genedata Expressionist® system to streamline their internal R&D process.

“We are working with tens of thousands of GeneChip® data sets. In the past, we were limited to normalizing small batches at a time. With Expressionist we can normalize the entire data set in one go,” said Mr. Junichi Muroya, member of the bioinformatics team at Chugai Pharmaceutical. “This has greatly increased processing speed, facilitated sophisticated statistical analysis and overall improved the quality of our results significantly.”

As part of their work in oncology and chronic diseases, researchers at Chugai have used Expressionist to perform a one-step, enterprise-wide normalization on their entire microarray data pool.  Expressionist was also used to standardize the workflow-based microarray quality control process and obtain fully comparable data for subsequent data analysis.

“We are excited to work with Chugai, one of the most innovative pharmaceutical companies in Japan,” said Dr. Othmar Pfannes, CEO of Genedata. “Our partnership with Chugai is another example of Genedata’s successful expansion in the Japanese market. It also demonstrates the positive impact of our cutting-edge software and services on R&D productivity and how this ultimately saves time and money for our partners.”

About Chugai

Chugai Pharmaceutical, specialized in prescription pharmaceuticals and based in Tokyo, is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Since the start of the strategic alliance with Roche in October 2002, Chugai is actively involved in prescription pharmaceutical R&D activities in Japan and abroad as an important member of the Roche Group.  Specifically, Chugai is working to develop innovative products with global applications, focusing on the oncology and chronic disease field. In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and Ukima is conducting research for technology development for industrial production. Overseas, Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe. The consolidated sales in 2008 of Chugai totalled 326.9 billion yen and the operating profit was 51.6 billion yen.  Chugai is aiming at the consolidated sales of 460 billion yen and operating profit of 80 billion yen in 2012, as stated in new mid-term business plan "Sunrise 2012". Additional information is available on the Internet at www.chugai-pharm.co.jp.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com

Contacts
Allison Kurz
Genedata
Marketing & Communications
Phone: +41 61 511 8459
communications@genedata.com

Jackie Thrasivoulos
Genedata
Public Relations
Phone: +1 508 881 3109
jackie.thrasivoulos@genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.